4 insurance Insurance-Laws-and-Products 
Patently O
NOVEMBER 27, 2023
An exotic insurance product has recently taken the litigation world by storm. Judgment preservation insurance, or JPI, was neither offered nor widely discussed, at least publicly, as recently as five years ago. [1] Guest post by Jonathan Stroud and Sam Korte. 2] In this example—taken from a pitch—a $12.5m There, the $47.5m
LawSites
APRIL 11, 2024
While the last few years have brought an abundance of new and innovative legal tech products to market, the fact of the matter is that not every new product will succeed. Inevitably, for whatever reason, some products fail. But one thing for certain is that while some products shut down with a whimper, others go out with a bang.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
FDA Law Blog
NOVEMBER 27, 2023
17, 2023, the Department of Justice (DOJ) announced the first-ever conviction of two corporate executives in a criminal prosecution for failure to report a consumer product defect under the CPSA. By Riëtte van Laack & Anne K. What led to this conviction? It is a long story that started more than a decade ago. and Gree USA Inc.
LDA PRO
DECEMBER 13, 2021
Paralegals are legal workers who are trained, educated, and have adequate knowledge of the law. Generally, there are 4 types of paralegals in the law industry: Traditional paralegals. Traditional paralegals are those who work under the supervision or administration of a lawyer or a law firm. Non-traditional paralegals.
FDA Law Blog
JANUARY 11, 2022
With the District Court of Delaware’s January 4 decision in a similar case (brought by GSK’s lawyers), Amarin v. The Court, however, would not dismiss similar allegations as applied to health insurer. Koblitz — Since the August 2021 decision in GSK v. Hikma , the generic industry can have some hope. In the wake of GSK v.
FDA Law Blog
JANUARY 11, 2022
With the District Court of Delaware’s January 4 decision in a similar case (brought by GSK’s lawyers), Amarin v. The Court, however, would not dismiss similar allegations as applied to health insurer. Koblitz — Since the August 2021 decision in GSK v. Hikma , the generic industry can have some hope. In the wake of GSK v.
Fordham Law News
OCTOBER 18, 2023
4] Historically, pharmaceutical companies, providers, and insurers have negotiated drug prices behind closed doors. 13] Alternatively, manufacturers could shift costs to private insurers.[14] 14] The Program’s impact on drug manufacturers’ profits and private insurers’ costs remains uncertain.
Expert insights. Personalized for you.
83 
Let's personalize your content